Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence DUBLIN - December 17, 2018 - Medtronic plc (MDT) today announced U.S. Food and Drug ...

The FDA has approved an app-based smart programming device used to discreetly and easily control implants treating for overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive ...

World’s Smallest Rechargeable Bladder/Bowel Control System — InterStim Micro — Features Trusted MRI Technology for Full-Body 1.5 and 3 Tesla MRI Scans Only Medtronic Offers Patients Personalized ...

DUBLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has begun recruitment of the prospective, multicenter, global, ...

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...

ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and ...

Sacral neuromodulation is an advanced therapy for people with bladder and bowel control issues that are not responding to other non-invasive therapies. The system works by targeting nerve signals that ...

DUBLIN, Feb. 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration ...

Full-Body MRI-Conditional InterStim II and InterStim Micro Systems Offer Lifestyle-Friendly Choices in Sacral Neuromodulation Therapy to Europeans Suffering from Incontinence DUBLIN, Jan. 13, 2020 ...

Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

The race to treat a number of health conditions using neurostimulation technology is a marathon, not a sprint—but Medtronic and Axonics Modulation Technologies are still aiming for a photo finish. For ...